BCM
INZY

Burrage Capital Management’s Inozyme Pharma INZY Stock Holding History

Burrage Capital Management’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-242,517
Closed -$4.13M – 10
2021
Q2 		$4.13M Buy
242,517
+73,044
+43% +$1.27M 4.14% 11
2021
Q1 		$3.36M Sell
169,473
-1,323
-0.8% -$29.2K 2.72% 19
2020
Q4 		$3.52M Buy
+170,796
New +$4.07M 2.69% 16

Other funds holding INZY

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Burrage Capital Management's INZY Position: Q3 2021 in Review

Burrage Capital Management sold out of Inozyme Pharma (INZY) in Q3 2021, closing a stake of 242,517 shares — an estimated $4.13M sold.

Burrage Capital Management first reported a position in INZY in Q4 2020 and held it in 3 quarters. The position peaked at $4.13M in Q2 2021. 52 funds tracked by Wall St. Rank hold INZY as of Q3 2021.

  • Burrage Capital Management reported no remaining Inozyme Pharma position as of Q3 2021 after selling out during the quarter.
  • Burrage Capital Management sold 242,517 Inozyme Pharma shares in Q3 2021, an estimated $4.13M.
  • Burrage Capital Management first reported a position in Inozyme Pharma in Q4 2020 and held it in 3 quarters.
  • Burrage Capital Management's Inozyme Pharma position peaked at $4.13M in Q2 2021.
  • 52 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2021.

Based on Burrage Capital Management's 13F filing for Q3 2021.